| 10.12 -0.1 (-0.98%) | 10-08 15:29 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 13.07 |
1-year : | 13.91 |
| Resists | First : | 11.19 |
Second : | 11.9 |
| Pivot price | 10.75 |
|||
| Supports | First : | 10.03 |
Second : | 8.34 |
| MAs | MA(5) : | 10.4 |
MA(20) : | 10.87 |
| MA(100) : | 10.57  |
MA(250) : | 11.3 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 8.3 |
D(3) : | 13 |
| RSI | RSI(14): 27.4 |
|||
| 52-week | High : | 14.56 | Low : | 9.02 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ FOLD ] has closed below the lower bollinger band by 1.1%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 2.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 10.62 - 10.68 | 10.68 - 10.73 |
| Low: | 10.02 - 10.1 | 10.1 - 10.17 |
| Close: | 10.1 - 10.22 | 10.22 - 10.32 |
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
Mon, 07 Oct 2024
Amicus Therapeutics (NASDAQ:FOLD) Upgraded to Buy by StockNews.com - MarketBeat
Mon, 07 Oct 2024
JPMorgan Chase & Co's Strategic Reduction in Amicus Therapeutics Inc - Yahoo Finance UK
Mon, 07 Oct 2024
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Mon, 07 Oct 2024
107,369 Shares in Amicus Therapeutics, Inc. (NASDAQ:FOLD) Bought by Bank of Montreal Can - MarketBeat
Fri, 04 Oct 2024
Amicus Therapeutics Announces Participation at the World Muscle Society Annual Congress 2024 - GlobeNewswire
Mon, 30 Sep 2024
When Will Amicus Therapeutics, Inc. (NASDAQ:FOLD) Become Profitable? - Simply Wall St
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 297 (M) |
| Shares Float | 239 (M) |
| Held by Insiders | 0.7 (%) |
| Held by Institutions | 107.6 (%) |
| Shares Short | 22,810 (K) |
| Shares Short P.Month | 24,040 (K) |
| EPS | -0.39 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.44 |
| Profit Margin | -26.3 % |
| Operating Margin | 11.8 % |
| Return on Assets (ttm) | -2.2 % |
| Return on Equity (ttm) | -98 % |
| Qtrly Rev. Growth | 34 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 1.53 |
| EBITDA (p.s.) | -0.06 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -42 (M) |
| Levered Free Cash Flow | 13 (M) |
| PE Ratio | -25.83 |
| PEG Ratio | 0.3 |
| Price to Book value | 22.37 |
| Price to Sales | 6.55 |
| Price to Cash Flow | -71.3 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|